<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582320</url>
  </required_header>
  <id_info>
    <org_study_id>LLC1415</org_study_id>
    <nct_id>NCT02582320</nct_id>
  </id_info>
  <brief_title>Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program</brief_title>
  <official_title>A Retrospective Study to Evaluate the Clinical-Biologic Characteristics and Outcome of Patients Treated in Italy According to the Ibrutinib-Named Patient Program for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective observational study aimed at describing the characteristics and&#xD;
      outcome of CLL patients included in the NPP in Italy in a period of time ranging from the&#xD;
      start of the NPP until November, 30th 2014. A longitudinal survey will be carried out by&#xD;
      collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be&#xD;
      observed for at least 12 months from the treatment start.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. The disease is&#xD;
      characterized by the progressive accumulation of phenotypically mature malignant B&#xD;
      lymphocytes, primarily in the peripheral blood, bone marrow, and lymph nodes. Over the last&#xD;
      10-15 years several biological prognostic markers have been identified, starting from the&#xD;
      immunoglobulin gene mutational analysis to CD38, ZAP70, CD49d expression, and many others.&#xD;
      The very recent discovery of several new genes that carry point mutations in CLL, including&#xD;
      NOTCH1, SF3B1 and BIRC3, has added more markers that seem to correlate with resistance to&#xD;
      treatment and with transformation into Richter syndrome. A large number of chemoimmunotherapy&#xD;
      regimens are currently considered for the treatment of CLL patients.&#xD;
&#xD;
      NPP program The Named Patient Program (NPP) is a program intended to provide early access to&#xD;
      ibrutinib in Italy. This program is specifically for patients who have relapsed or refractory&#xD;
      chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma.&#xD;
&#xD;
      Rationale In patients with CLL Ibrutinib, given as single agent has shown marked activity and&#xD;
      a good safety profile. Data from patients treated with ibrutinib outside a controlled&#xD;
      clinical trial within a National Patient Program (NPP) could give additional information&#xD;
      about the clinical use, treatment duration, efficacy, and toxicity of ibrutinib given to CLL&#xD;
      patients in a real life context.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">October 3, 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who progress</measure>
    <time_frame>At 12 months from the start of Ibrutinib</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who respond to treatment</measure>
    <time_frame>At 12 months from enrolment</time_frame>
    <description>CR,PR, L-PR according to the IWCLL 2008 criteria with modification for treatment-related lymphocytosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>At 12 months from enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment in terms of number of days needed</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients surviving</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who reach normal values in the immunoglobulin levels</measure>
    <time_frame>At 3, 6 and 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with toxic events</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who develop Richter's syndrome and secondary malignancies</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who require added assistance</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>For example: hospitalization, emergency visits, blood product transfusions and use of hematopoietic growth factors, antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who fail to treatment.</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">264</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Study patients</arm_group_label>
    <description>Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.</description>
    <arm_group_label>Study patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with R/R CLL or 17p deleted CLL fulfilling the eligibility criteria required by&#xD;
        the NPP who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        NPP Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥18 years of age.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.&#xD;
&#xD;
          3. A minimum of one prior line of systemic chemotherapy, chemo-immunotherapy, or an&#xD;
             alemtuzumab-based regimen, consisting of at least two cycles of therapy.&#xD;
&#xD;
          4. Relapsed or refractory CLL with one or more of the following criteria:&#xD;
&#xD;
               -  Presence of deletion of the short-arm of chromosome 17 (ie 17p deletion).&#xD;
&#xD;
               -  Relapsed: Failed two or more previous treatments, at least one with a purine&#xD;
                  analogue such as fludarabine.&#xD;
&#xD;
               -  Relapsed: Progression-free interval of less than 24 months from completing&#xD;
                  treatment with a nucleoside analogue, or bendamustine-containing regimen in&#xD;
                  combination with an anti-CD20 monoclonal antibody such as rituximab.&#xD;
&#xD;
               -  Refractory: Failure to respond to a prior chemotherapy-based treatment, stable&#xD;
                  disease, or disease progression while on treatment.&#xD;
&#xD;
          5. Patient has active CLL requiring treatment as defined by the IWCLL 2008 criteria. A&#xD;
             minimum of one of the following criteria is required:&#xD;
&#xD;
               -  Evidence of progressive marrow failure, as manifested by the development of, or&#xD;
                  worsening of, anemia or thrombocytopenia.&#xD;
&#xD;
               -  Massive (at least 6 cm below the left costal margin), progressive, or symptomatic&#xD;
                  splenomegaly.&#xD;
&#xD;
                  c. Massive nodes (at least 10 cm in longest diameter), progressive, or&#xD;
                  symptomatic lymphadenopathy.&#xD;
&#xD;
               -  Progressive lymphocytosis with an increase of more than 50% over a 2-month period&#xD;
                  or a lymphocyte doubling time of less than 6 months (which may be extrapolated).&#xD;
                  For patients with initial blood lymphocyte counts of less than 30 x 109/L&#xD;
                  (30,000/mL), lymphocyte doubling time should not be used as a single parameter to&#xD;
                  define indication for treatment. Factors contributing to lymphocytosis or&#xD;
                  lymphadenopathy other than CLL (e.g., infections) should be excluded.&#xD;
&#xD;
               -  Constitutional symptoms, defined as 1 or more of the following disease-related&#xD;
                  symptoms or signs:&#xD;
&#xD;
                  i. Unintentional weight loss &gt;10% within the previous 6 months prior to&#xD;
                  screening.&#xD;
&#xD;
             ii. Significant fatigue (inability to work or perform usual activities). iii. Fever&#xD;
             higher than 38.0°C for 2 or more weeks without evidence of infection.&#xD;
&#xD;
             iv. Night sweats for more than 1 month without evidence of infection.&#xD;
&#xD;
          6. Haematology values within the following parameters:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) of ≥0.75 x109/L independent of growth factor&#xD;
                  support.&#xD;
&#xD;
               -  Platelet count of ≥30 x109/L independent of platelet support.&#xD;
&#xD;
          7. Biochemical values within the following limits:&#xD;
&#xD;
               -  Serum creatinine ≤2 times the upper limit of normal (ULN) or estimated glomerular&#xD;
                  filtration rate (GFR [Crockcoft-Gault]) ≥30 mL/minute.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times&#xD;
                  ULN.&#xD;
&#xD;
               -  Total bilirubin ≤1.5 times ULN (unless the bilirubin rise is due to Gilbert's&#xD;
                  syndrome or of non-hepatic origin) for whom the upper limit of serum bilirubin is&#xD;
                  3 mg/dl.&#xD;
&#xD;
          8. No problems to swallowing regularly capsules.&#xD;
&#xD;
          9. Agreed to practice a highly effective method of birth control during and after&#xD;
             participation in the NPP if they are of childbearing potential and sexually active.&#xD;
&#xD;
         10. Signed informed consent document (if feasible) indicating that they understand the&#xD;
             purpose of the study, they agree to give complete access to their medical records.&#xD;
&#xD;
        NPP Exclusion criteria&#xD;
&#xD;
          1. Previous treatment with ibrutinib or participation to an ibrutinib clinical trial&#xD;
             (ibrutinib or comparator arm).&#xD;
&#xD;
          2. Eligible to participate in a currently recruiting ibrutinib clinical trial.&#xD;
&#xD;
          3. Previously received ibrutinib as part of a clinical trial.&#xD;
&#xD;
          4. Previously received a Bruton's tyrosine kinase (BTK) inhibitor other than ibrutinib.&#xD;
&#xD;
          5. Currently enrolled in an interventional clinical trial.&#xD;
&#xD;
          6. Currently receiving chemotherapy, anticancer immunotherapy, or experimental therapy.&#xD;
&#xD;
          7. Currently recovering from acute toxicities of prior treatment for CLL.&#xD;
&#xD;
          8. Received stem cell transplantation within the past 6 months.&#xD;
&#xD;
          9. Evidence of graft-versus-host disease and/or requires immunosuppressant therapy.&#xD;
&#xD;
         10. Major surgery within the past 4 weeks or a major wound that has not fully healed.&#xD;
&#xD;
         11. History of human immunodeficiency virus (HIV) or active infection with Hepatitis C or&#xD;
             B.&#xD;
&#xD;
         12. Ongoing uncontrolled active systemic infection.&#xD;
&#xD;
         13. Uncontrolled autoimmune haemolytic anemia (AIHA).&#xD;
&#xD;
         14. Uncontrolled idiopathic thrombocytopenic purpura (ITP).&#xD;
&#xD;
         15. Central nervous system leukemia/lymphoma or Richter's transformation.&#xD;
&#xD;
         16. Diagnosed or treated for another malignancy, other than CLL, except for:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease present&#xD;
                  for ≥3 years prior to entering this named patient program and considered to be at&#xD;
                  low risk for recurrence.&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease.&#xD;
&#xD;
               -  Adequately treated cervical carcinoma in situ without evidence of disease.&#xD;
&#xD;
         17. Stroke within the past 6 months.&#xD;
&#xD;
         18. Intracranial haemorrhage within the past 6 months.&#xD;
&#xD;
         19. Requires anticoagulation with warfarin or equivalent vitamin K antagonist (e.g.&#xD;
             phenprocoumon).&#xD;
&#xD;
         20. Requires treatment with a strong CYP3A inhibitor.&#xD;
&#xD;
         21. Clinically significant cardiovascular disease such as:&#xD;
&#xD;
               -  Uncontrolled or symptomatic arrhythmias.&#xD;
&#xD;
               -  Congestive heart failure.&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months.&#xD;
&#xD;
               -  Class 3 or 4 cardiac disease as defined by the New York Heart Association&#xD;
                  Functional Classification.&#xD;
&#xD;
         22. Patient has any life-threatening illness, medical condition, clinically significant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Foà</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinico Umberto I, Hematology Department.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Terapia Cellulare - Ospedale &quot;C. e G. Mazzoni&quot; di Ascoli Piceno</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C di Ematologia P.O. &quot;S.Giuseppe Moscati&quot; - 2° piano</name>
      <address>
        <city>Aversa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Medicina Interna - ASUR Marche 8 - Ospedale Civile</name>
      <address>
        <city>Civitanova Marche</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST.Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara di Sicilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncoematologia di Nocera Inferiore-plesso ospedaliero &quot;A. Tortora&quot; di Pagani del DEA Nocera-Pagani</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - IRCCS Centro oncologico della Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.S.A. Ematologia ASL RMA Presidio Nuovo Regina Margherita</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I, Hematology Department - Sapienza</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia Cancer Center Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS N.6 Osp. S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

